This Government Contract opportunity from Department Of Defense was posted on November 22, 2016. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

PHARMACEUTICAL CEC AWARD

Awarded

SPE2D0-15-R-0002Federal

Submission Closed11/16/2016, 12:00:00 AM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325412

New

International

Pralidoxime Chloride/Methyl Sulfate ManufacturingThis subcontract involves the manufacture and supply of Pralidoxime chloride or methyl sulfate in solution or powder form for injection to support prime contractors on Department of National Defence projects. The required product must have a dosage strength of at least 200 mg per container and a minimum shelf-life of 36 months. The selected provider is responsible for conducting stability testing, providing quality assurance certification, and delivering complete treatment courses along with stability reports and product monographs. To be eligible, the manufacturer must hold a Health Canada Notice of Compliance under Division 8 or Division 11 authorization. This global procurement opportunity is managed by the Government of Canada and allows for performance across various international regions. Interested parties must submit their responses by November 10, 2026.

Department of National Defence

POSTED

DEADLINE

SLS Printer Consumables and Maintenance KitsThis subcontract focuses on the provision of specialized consumables and wear-and-tear replacement parts to support prime contractors working on Department of National Defence projects for the Government of Canada. The scope of supply includes engineering-grade thermoplastic powders such as PA 11, PA 12, PP, and TPU, along with critical SLS hardware components including optical cassettes, recoater blades, infrared heaters, sealing foam gaskets, and build chambers. All bulk consumables and spare parts kits are to be delivered to CFB Petawawa. The opportunity was posted on October 20, 2026, with a response deadline of November 2, 2026, falling under NAICS code 325412.

Department of National Defence

POSTED

DEADLINE

Supplier of Red Sealing Compound (NSN 8030015650423)This subcontract involves the supply of red sealing compound, identified by NSN 8030015650423, for prime contractors working under the Defense Logistics Agency. The material must be provided in 10.00 milliliter containers and strictly adhere to the DLA Master List of Technical and Quality Requirements RA001. The supplier is responsible for managing TYPE I (CODE H) shelf-life requirements and ensuring all packaging complies with MIL-STD-2073-1E and MIL-STD-129 standards. Additionally, the contractor must provide all necessary safety documentation, including SDS and HazCom labels in accordance with 29 C.F.R. 1910.1200. The performance of this contract is centered in FPO 09591-0100, with the primary objective being the delivery of packaged sealing compound and its associated safety certifications to the Department of Defense.

Defense Logistics Agency

POSTED

DEADLINE

Active Pharmaceutical Ingredient (API) SupplyThis subcontract for Active Pharmaceutical Ingredient (API) Supply involves the synthesis, purification, and bulk delivery of pharmaceutical-grade Benzocaine and Menthol. The provider supports prime contractors fulfilling requirements for the Department of Defense Medical Supply Chain Pharm FSA, ensuring all raw chemical components meet strict USP and ISO manufacturing standards through the use of HPLC purity testing. The performance of this contract is centered at Fort Campbell, Kentucky, under NAICS code 325412. The solicitation was posted on October 19, 2026, with a response deadline of October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Benzocaine and Menthol Lozenge SupplyThis subcontract involves the manufacture and supply of finished Benzocaine and Menthol lozenges to prime contractors supporting the Department of Defense Medical Supply Chain Pharm FSA. The provider is responsible for producing and quality-testing pharmaceutical lozenges within FDA-compliant facilities adhering to Good Manufacturing Practice standards to ensure all delivered quantities meet strict government specifications. Administrative processes for this requirement are managed through the DLA Internet Bid Board System for quote submissions. The performance of the contract is centered at Fort Campbell, and the procurement falls under NAICS code 325412 for pharmaceutical preparation.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Moxifloxacin Hydrochloride Tablets (400 MG)This subcontract, managed by the Medical Supply Chain Pharm FSA under the Department of Defense, involves the manufacture and supply of pharmaceutical-grade Moxifloxacin Hydrochloride Tablets (400 MG). The contractor is responsible for providing the antibiotic tablets in 30-count bottles, ensuring all products are sourced or manufactured in accordance with Good Manufacturing Practices and FDA approval and registration requirements. Logistical compliance is critical, as the contract mandates adherence to RP001 DLA Packaging Requirements and the use of climate-controlled storage and transport to maintain product integrity. Performance will take place in FPO 09591, with the primary objective of supporting prime contractors on DLA supply contracts.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Activated Charcoal, SuspensionThis subcontract, issued by the Medical Supply Chain Pharm FSA under the Department of Defense, requires the provision of activated charcoal in suspension form, identified by NSN 6505012828880. The materials must be delivered to the USS Lewis B Puller ESB 3, with all shipments adhering to strict DLA packaging requirements and technical specifications. The contract falls under NAICS code 325412 and is intended for prime contractors supporting DLA supply operations. Resellers are specifically required to comply with the Non-Manufacturer Rule to ensure eligibility. The performance location is designated as FPO 09591, with a response deadline set for October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of 4% Chlorhexidine Gluconate Surgical DetergentThis subcontract involves the supply of FDA-regulated 4% Chlorhexidine Gluconate surgical detergent for prime contractors supporting Department of Defense supply contracts. The provider is responsible for manufacturing or sourcing the chemical compound in strict accordance with NSN 6505-01-101-3759 specifications and DLA Packaging Requirements RP001. To maintain quality and regulatory compliance, the product must be produced in FDA-approved pharmaceutical manufacturing facilities. The contract mandates a total shelf life of 24 months, with a requirement that the detergent possesses at least 21 months of remaining shelf life at the time of delivery. Managed under the Medical Supply Chain Pharm FSA, the performance of this contract is centered in FPO 96660, falling under NAICS code 325412.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Bupivacaine and Epinephrine InjectionThis subcontract involves the supply of Bupivacaine and Epinephrine Injection to prime contractors supporting DLA Troop Support medical supply contracts. The provider must deliver end items compliant with NSN 6505-01-189-3973, utilizing pharmaceutical-grade materials and medical-grade packaging. To qualify, the supplier is required to hold all necessary pharmaceutical manufacturing licenses and maintain FDA approval for the specific drug formulation. Managed by the Department of Defense under the Medical Supply Chain Pharm FSA, the contract specifies the delivery of injectable medication quantities as outlined in the award. The performance location is designated as FPO 09591, and the procurement falls under NAICS code 325412.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Isoniazid Tablet ManufacturingThis subcontract involves the manufacturing of Isoniazid 300 MG tablets for prime contractors supporting Department of Defense pharmaceutical supply contracts through the Medical Supply Chain Pharm FSA. The manufacturer is responsible for producing tablets that conform to United States Pharmacopeia standards, packaged in bottles of 100 units. To execute this contract, the provider must utilize pharmaceutical grade API, specialized tablet pressing equipment, and a USP-compliant quality control laboratory. Strict regulatory adherence is required, including the maintenance of active FDA registration and continuous USP compliance. The performance of this contract is centered in FPO 09591, with the primary objective of delivering finished pharmaceutical products that meet all specified government quality and safety benchmarks.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Tetrahydrozoline Hydrochloride Ophthalmic Solution SupplierThis subcontract involves the supply of Tetrahydrozoline Hydrochloride Ophthalmic Solution, USP (0.05%, 15 ML) to support prime contractors under DLA Troop Support medical supply contracts. The selected provider is responsible for manufacturing or sourcing the pharmaceutical solution in accordance with USP standards, utilizing sterile ophthalmic bottling and packaging. All operations must comply with FDA approval and registration requirements for pharmaceutical manufacturing. The contract is managed by the Department of Defense under the Medical Supply Chain Pharm FSA. Physical deliveries of the ophthalmic solution are to be made to either the prime contractor or the Naval Med Readiness Logistics Command, with the place of performance located in Williamsburg, Virginia.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Tolnaftate Powder, USP 1%This subcontract through the Department of Defense Medical Supply Chain Pharm FSA involves the supply of Tolnaftate Powder, USP 1%, to prime contractors on DLA Troop Support medical supply contracts. The requirement is for 15 bottles of 45 GM powder, identified by NSN 6505014807897, which must strictly adhere to USP 1% standards and the DLA Master List of Technical and Quality Requirements. Eligible providers must possess the necessary pharmaceutical manufacturing and distribution licenses to fulfill the order. The performance of this contract is designated for FPO 09591, with a response deadline set for October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 6 days

AI Contract Overview

Awarded on November 16, 2016, by DLA Troop Support, this Pharmaceutical Corporate Exigency Contract (CEC) is an Indefinite Delivery/Indefinite Quantity, Fixed-Price contract with Economic Price Adjustment clauses. The program establishes strategic partnerships between the Department of Defense and industry partners, including AstraZeneca Pharmaceuticals LP, Eagle Pharmaceuticals, Inc., and Hikma Pharmaceuticals USA Inc., to ensure the industrial base can meet increased demand for critical pharmaceutical items during mobilization, war, or other contingencies. The contract structure typically consists of a one-year base period with nine subsequent one-year option periods, allowing for a total potential duration of ten years. The contract focuses on securing access to various pharmaceutical product line items through the management of Total Guaranteed Coverage (TGC). Key financial mechanisms include Inventory Management Fees and Inventory Holding Fees, which are subject to periodic adjustments based on economic price indices. Throughout the contract lifecycle, numerous modifications have been implemented to exercise option years, update product pricing, add or delete line items, and incorporate updated federal regulations, such as Wide Area Workflow payment instructions and prohibitions on certain telecommunications equipment. Performance is managed through strict requirements for FDA approval, cold chain management, and specific packaging and labeling standards to ensure readiness for military operations.

General Info

Agency

Department Of Defense → Defense Logistics Agency

Contract Value

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Place of Performance

700 Robbins Ave DLA Troop Support -Medical, PHILADELPHIA, PA, 19111, USA

Set-Aside

NONE

Awardee

ASTRAZENECA PHARMACEUTICAL LP 1800 CONCORD PIKE WILMINGTON DE 19803 USA

Award Issued Date

11/16/2016, 12:00:00 AM UTC

Documents

Addendum to 52.212-1 Proposal Preparation and Organization

amendment

High

P00022 Contract Modification for SPE2D0-18-D-0006

modification

High

SPE2D015R00020007 - Preservation, Packaging, Packing, Labeling, and Marking (PPPL&M)

specifications

High

SPE2D015R00020009 - Proposal Submission Checklist

rfp

High

SPE2D015R00020010 CLIN Schedule and Option Period Fees

contract-document

High

SPE2D015R00020011 Addendum to 52.212-1 Proposal Preparation

amendment

High

SPE2D015R0002 Amendment 0001

amendment

High

SPE2D015R0002 Amendment 0002

amendment

High

SPE2D015R0002 Amendment 0003

amendment

High

SPE2D015R0002 Amendment 0004

amendment

High

SPE2D015R0002 Amendment 0005

amendment

High

SPE2D015R0002 Amendment 0006

amendment

High

SPE2D015R0002 Amendment 0007

amendment

High

SPE2D015R0002 Amendment 0008

amendment

High

SPE2D015R0002 Amendment 0009

amendment

High

SPE2D015R0002 Amendment 0010

amendment

High

SPE2D015R0002 Amendment 0011

amendment

High

SPE2D015R0002 Amendment 0012

amendment

High

SPE2D0-15-R-0002 Solicitation

rfp

High

SPE2D0-17-D-0002 Modification P00001

3 pages · modification

High

SPE2D0-17-D-0002 Modification P00006

8 pages · modification

High

SPE2D0-17-D-0002 Modification P00008

3 pages · modification

High

SPE2D0-17-D-0002 Modification P00010

3 pages · modification

High

SPE2D0-17-D-0002 Modification P00011

modification

High

SPE2D0-17-D-0002 Modification P00012

2 pages · modification

High

SPE2D0-17-D-0002 Modification P00013

modification

High

SPE2D0-17-D-0002 Modification P00014

4 pages · modification

High

SPE2D0-17-D-0002 P00005 Modification

modification

High

SPE2D0-17-D-0002 P00007 Amendment/Modification

modification

High

SPE2D0-17-D-0002 P00009 Modification

modification

High

SPE2D0-17-D-0002 P00015 - Modification

3 pages · modification

High

SPE2D0-17-D-0002 P00016 Amendment/Modification

4 pages · modification

High

SPE2D0-17-D-0002 P00017 - Modification

2 pages · modification

High

SPE2D0-17-D-0002 P00018 - Contract Modification

6 pages · modification

High

SPE2D0-17-D-0002 P00019 Modification

4 pages · modification

High

SPE2D0-17-D-0002 P00020 Modification

modification

High

SPE2D0-17-D-0002 P00021 Modification exercising Option Year 9

3 pages · modification

High

SPE2D0-17-D-0002 P00022 Contract Modification

modification

High

SPE2D0-18-D-0006 Modification P00011

2 pages · modification

High

SPE2D0-18-D-0006 Modification P00013

modification

High

SPE2D0-18-D-0006 Modification P00014

modification

High

SPE2D0-18-D-0006 Modification P00015

modification

High

SPE2D0-18-D-0006 Modification P00017

modification

High

SPE2D0-18-D-0006 P00001 Amendment

amendment

High

SPE2D0-18-D-0006 P00004 Amendment exercising option year 1

modification

High

SPE2D0-18-D-0006 P00007 Amendment/Modification

5 pages · modification

High

SPE2D0-18-D-0006 P00008 Modification

modification

High

SPE2D0-18-D-0006 P00009 Contract Modification

5 pages · modification

High

SPE2D0-18-D-0006 P00010 - Modification

modification

High

SPE2D0-18-D-0006 P00012 Amendment/Modification

modification

High

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseAwarded

PostedAug 13

Presolicitation

Type ChangedSep 1

Presolicitation → Solicitation

AwardedNov 16

Contract was awarded

Submission Closed

11/16/2016, 12:00:00 AM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Defense → Defense Logistics Agency

Contacts2 people available

OfficeN/A

Organization / AgencyDepartment Of Defense → Defense Logistics Agency

Office AddressN/A

Contacts

Sunday O. OladeleAcquisition Specialist

contact@example.gov

+1 (555) 000-0000

Melissa McMichaelAcquisition Specialist

contact@example.gov

+1 (555) 000-0000

Full Description

On November 16, 2016, DLA Troop Support awarded an Indefinite Delivery/Indefinite Quantity, Fixed-Price Contract with Economic Price Adjustment (EPA) clauses to AstraZeneca Pharmaceuticals LP. This Pharmaceutical Corporate Exigency Contract (CEC) consists of a one (1) base year, with the option to extend the contract for each of nine (9), one-year option periods. The Pharmaceutical CEC Program establishes partnerships between the Department of Defense (DoD) and industry to ensure that the industrial base is prepared to respond to the Military Services increased demand for items designated as critical during times of mobilization, war, contingency and military operations. This contract purchases access for various pharmaceutical product line items.